Nwam LLC Purchases 83,454 Shares of CRISPR Therapeutics AG $CRSP

Nwam LLC increased its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 455.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 101,769 shares of the company’s stock after acquiring an additional 83,454 shares during the period. Nwam LLC owned about 0.11% of CRISPR Therapeutics worth $6,770,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Royal Bank of Canada grew its position in shares of CRISPR Therapeutics by 28.2% during the 1st quarter. Royal Bank of Canada now owns 142,696 shares of the company’s stock valued at $4,856,000 after acquiring an additional 31,392 shares during the period. AQR Capital Management LLC bought a new position in CRISPR Therapeutics during the first quarter worth about $861,000. Woodline Partners LP boosted its position in CRISPR Therapeutics by 34.3% during the first quarter. Woodline Partners LP now owns 136,483 shares of the company’s stock worth $4,645,000 after purchasing an additional 34,883 shares during the period. Voya Investment Management LLC grew its stake in CRISPR Therapeutics by 60.2% in the 1st quarter. Voya Investment Management LLC now owns 13,870 shares of the company’s stock valued at $472,000 after buying an additional 5,210 shares in the last quarter. Finally, Exchange Traded Concepts LLC purchased a new position in shares of CRISPR Therapeutics in the second quarter valued at $903,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

Shares of CRSP stock opened at $54.12 on Friday. The company has a market capitalization of $5.16 billion, a P/E ratio of -9.68 and a beta of 1.70. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $78.48. The stock has a 50 day moving average price of $54.74 and a two-hundred day moving average price of $58.20.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, November 10th. The company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.15. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.23%. The company had revenue of $0.89 million for the quarter, compared to the consensus estimate of $8.74 million. As a group, equities analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on CRSP shares. Needham & Company LLC restated a “buy” rating and issued a $80.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, December 23rd. JPMorgan Chase & Co. initiated coverage on shares of CRISPR Therapeutics in a report on Thursday, September 18th. They issued an “overweight” rating and a $70.00 price target for the company. Citizens Jmp reaffirmed a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, December 23rd. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, September 23rd. Finally, Bank of America raised their target price on shares of CRISPR Therapeutics from $78.00 to $93.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Twelve investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $68.35.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.